Results 1 to 10 of about 799,218 (270)

Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes

open access: yesFrontiers in Immunology, 2018
Interleukin (IL)-4 and IL-13 are related cytokines that regulate many aspects of allergic inflammation. They play important roles in regulating the responses of lymphocytes, myeloid cells, and non-hematopoietic cells.
Ilkka S. Junttila, Ilkka S. Junttila
doaj   +2 more sources

IL-10 inhibits cytokine production by activated macrophages. [PDF]

open access: bronzeJournal of Immunology, 1991
IL-10 inhibits the ability of macrophage but not B cell APC to stimulate cytokine synthesis by Th1 T cell clones. In this study we have examined the direct effects of IL-10 on both macrophage cell lines and normal peritoneal macrophages.
David Fiorentino   +4 more
openalex   +2 more sources

IFN-I inducible miR-3614-5p targets ADAR1 isoforms and fine tunes innate immune activation

open access: yesFrontiers in Immunology, 2022
Regulation of innate immune responses is essential for maintenance of immune homeostasis and development of an appropriate immunity against microbial infection.
Françoise Vuillier   +13 more
doaj   +1 more source

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

open access: yesScientific Reports, 2021
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels   +9 more
doaj   +1 more source

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

open access: yesNature Communications, 2022
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab.
Sheila K. Pierson   +11 more
doaj   +1 more source

Human Ubiquitin-Specific Peptidase 18 Is Regulated by microRNAs via the 3'Untranslated Region, A Sequence Duplicated in Long Intergenic Non-coding RNA Genes Residing in chr22q11.21

open access: yesFrontiers in Genetics, 2021
Ubiquitin-specific peptidase 18 (USP18) acts as gatekeeper of type I interferon (IFN) responses by binding to the IFN receptor subunit IFNAR2 and preventing activation of the downstream JAK/STAT pathway.
Erminia Rubino   +12 more
doaj   +1 more source

Role of FK506-sensitive signals in asthmatic lung inflammation

open access: yesFrontiers in Immunology, 2022
Asthma is airway inflammatory diseases caused by the activation of group 2 innate lymphoid cells (ILC2s) and type 2 helper T (TH2) cells. Cysteine proteases allergen cause tissue damage to airway epithelial cells and activate ILC2-mediated type 2 airway ...
Chihiro Tomiaki   +8 more
doaj   +1 more source

Comparison of the Seven Interleukin-32 Isoforms’ Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity

open access: yesFrontiers in Immunology, 2022
Cytokines are significantly associated with the homeostasis of immune responses in health and disease. Interleukin-32 (IL-32) is a cytokine originally discovered in natural killer cell transcript 4.
Saerok Shim   +16 more
doaj   +1 more source

A Paradoxical Effect of Interleukin-32 Isoforms on Cancer

open access: yesFrontiers in Immunology, 2022
IL-32 plays a contradictory role such as tumor proliferation or suppressor in cancer development depending on the cancer type. In most cancers, it was found that the high expression of IL-32 was associated with more proliferative and progression of ...
Saerok Shim   +17 more
doaj   +1 more source

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment

open access: yesFrontiers in Immunology, 2021
BackgroundInterferon beta (IFNβ) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades.
Priyanka Devi-Marulkar   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy